Food Allergy Treatments Under Development Highlighted in 2026 Report
A new report details ongoing developments in food allergy therapies, including clinical trials and FDA approvals. Over 30 treatment options are currently in the pipeline.
Market analysis firm DelveInsight released its 2026 report in June, summarizing global advancements in the development of food allergy treatments. The analysis indicates over 30 therapies are currently in development, pursued by more than 25 companies.
The report, titled "Food Allergy Pipeline Insight, 2026," provides a comprehensive overview of the clinical development landscape for food allergy treatments, from preclinical stages to market entry. It details drug mechanisms of action, clinical study data, regulatory approvals, and product development activities, including collaborations and funding.
Key companies involved in developing these therapies include Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, and GI Innovation. Prominent therapies in various stages of development are INT301, AIMab7195, VE416, ADP101, and Dupilumab.
Recent developments mentioned in the report include Aquestive Therapeutics receiving a Complete Response Letter (CRL) from the FDA for its dibutepinephrine drug in February 2026. Additionally, Celltrion received FDA approval for an omalizumab biosimilar in December 2025, marking progress in bringing new treatment options to patients.